LIXTE, Netherlands Cancer Institute, And Oncode Institute To Expand Collaboration
Portfolio Pulse from Benzinga Newsdesk
LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) has announced an extension of its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE's lead clinical compound, LB-100, with immunotherapy in various cancers. The two-year extension follows a successful collaboration in identifying promising drugs to be combined with LB-100 for treating colon cancer.
October 16, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The extended collaboration between LIXTE, NKI, and Oncode Institute could potentially lead to the development of more effective cancer treatments, which could boost LIXTE's reputation and potentially its stock price.
The extended collaboration signifies a successful previous partnership and could lead to the development of more effective cancer treatments. This could increase the value of LIXTE's lead clinical compound, LB-100, and potentially boost the company's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100